Skip to Content
Cancer Diagnosis Program (CDP) — Biorepositories & Biospecimen Research Branch (BBRB) Cancer Diagnosis Program (CDP) Biorepositories & Biospecimen Research Branch (BBRB)
Contact NExT
Show menu
Search this site
Last Updated: 07/25/14

2008 BRN Symposium Bibliography

(in alphabetical order)

Brian M. Balgley, M.D., Ph.D.

  1. Xu H., et al. Antigen Retrieval for Proteomic Characterization of Formalin-Fixed and Paraffin-Embedded Tissues. J Proteome Res, 2008.
  2. Fang X., et al. Comparison of Electrokinetics-Based Multidimensional Separations Coupled with Electrospray Ionization-Tandem Mass Spectrometry for Characterization of Human Salivary Proteins. Anal Chem 79:578592, 2007.
  3. Guo T., et al. Proteome Analysis of Microdissected Formalin-Fixed and Paraffin-Embedded Tissue Specimens. J Histochem Cytochem 55:763-72, 2007.

Guido Brink, M.S.

  1. Jolien M.B., et al. Use of 70-Gene Signature to Predict Prognosis of Patients With Node-Negative Breast Cancer: A Prospective Community-Based Feasibility Study (RASTER). The Lancet Oncology 8:1079-87, 2007.

Patrick O. Brown, M.D., Ph.D.

  1. Marinelli R.J., et al. The Stanford Tissue Microarray Database. Nucleic Acids Res 36:D871-77, 2008.
  2. Chi J.T., et al. Gene Expression Programs of Human Smooth Muscle Cells: Tissue-Specific Differentiation and Prognostic Significance in Breast Cancers. PLoS Genet 3:1770-84, 2007.
  3. Klapholz-Brown Z., et al. Transcriptional Program Induced by Wnt Protein in Human Fibroblasts Suggests Mechanisms for Cell Cooperativity in Defining Tissue Microenvironments. PLoS ONE 2:e945, 2006.
  4. Lowe A.W., et al. Gene Expression Patterns in Pancreatic Tumors, Cells and Tissues PLoS ONE 2:e323, 2007.
  5. van de Rijn M., et al. Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas With Poor Clinical Outcome. Am J Pathol 161:1991-6, 2002.

Kevin Camphausen, M.D.

  1. Kirk M.J., et al. Non-Patient Related Variables Affecting Levels of Vascular Endothelial Growth Factor in Urine Biospecimens. J Cell Mol Med, 2007,
  2. Menard C., et al., Discovering Clinical Biomarkers of Ionizing Radiation Exposure With Serum Proteomic Analysis. Cancer Res 66:1844-50, 2006.
  3. Folkman J, Camphausen K. Cancer. What Does Radiotherapy Do to Endothelial Cells? Science 293:227-8, 2001.

Carolyn C. Compton, M.D., Ph.D.

  1. Compton C. Getting to Personalized Cancer Medicine: Taking Out the Garbage. Cancer 110:1641-3, 2007.
  2. Bilchik A.J., Compton C. Close Collaboration Between Surgeon and Pathologist Is Essential for Accurate Staging of Early Colon Cancer. Ann Surg 245:864-6, 2007.
  3. Compton C. Key Issues in Reporting Common Cancer Specimens: Problems in Pathologic Staging of Colon Cancer. Arch Pathol Lab Med 130:318-24, 2006.

Angelo M. De Marzo, M.D., Ph.D.

  1. De Marzo A.M., Fedor H., Gage W.R., Rubin M.A. Inadequate Formalin Fixation Reduces Reliability of p27Kip1 Immunohistochemical Staining: Probing Optimal Fixation Time Using High-Density Tissue Microarrays. Hum Path 33:756-60, 2002.
  2. Meeker A.K., Hicks J.L., Platz E.A., March G.E., Bennett C.J., Delannoy M.J., De Marzo, A.M. Telomere Shortening Is an Early Somatic DNA Alteration in Human Prostate Tumorigenesis. Cancer Res 62:6405-9, 2002.
  3. De Marzo A.M., Platz E.A., Sutcliffe S., Xu J., Gronberg H., Drake C.G., Nakai Y., Isaacs W.B., Nelson W.G. Inflammation in Prostate Carcinogenesis. Nat Rev Cancer 7:256-69, 2007.

Theo deVos, Ph.D., M.S.P.H.

  1. Lofton-Day C., et al. DNA Methylation Biomarkers for Blood-Based Colorectal Cancer Screening. Clin Chem 54:414-23, 2008.

William E. Grizzle, M.D., Ph.D.

  1. Reynolds P.N., Nicklin S.A., Kaliberova L., Boatman B.G., Grizzle W.E., Balyasnikova I.V., Baker A.H., Danilov S.M., Curiel D.T. Combined Transductional and Transcriptional Targeting Improves the Specificity of Transgene Expression In Vivo. Nat Biotechnol 19:838-42, 2001.
  2. Stonecypher M.S., Byer S.J., Grizzle W.E., Carroll S.L. Activation of the Neuregulin-1/ErbB Signaling Pathway Promotes the Proliferation of Neoplastic Schwann Cells in Human Malignant Peripheral Nerve Sheath Tumors. Oncogene 24:5589-605, 2005.
  3. Jhala N., Jhala D., Vickers S.M., Eltoum I., Batra S.K., Manne U., Eloubeidi M., Jones J.J., Grizzle W.E. Biomarkers in Diagnosis of Pancreatic Carcinoma in Fine-Needle Aspirates: A Model for Translational Research Application. Am J Clin Pathol 126:572-9, 2006.
  4. Chakrabarti R., Jones J.L., Oelschlager D.K., Tapia T., Tousson A., Grizzle W.E. Phosphorylated LIM Kinases Colocalize With Gamma-Tubulin in Centrosomes During Early Stages of Mitosis. Cell Cycle 6:2944-52, 2007.

Steven Gutman, M.D., M.B.A.

  1. Gutman S., Hackett J. Search for Shortcuts on the Critical Path to Market: US FDA Perspectives From the Diagnostic Side. Pharmacogenomics 7:1223-7, 2006.
  2. Gutman S., Kessler L.G. The US Food and Drug Administration Perspective on Cancer Biomarker Development. Nat Rev Cancer 6:565-71, 2006.
  3. Gutman S., Meyer D. Lexicon for Laboratories-Scaling the Tower of Babel. Arch Pathol Lab Med 127:625-6, 2003.

M. Elizabeth H. Hammond, M.D., FCAP

  1. Wolff A.C., et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 131:18, 2007.
  2. Kfoury A.G., et al. Impact of Repetitive Episodes of Antibody-Mediated or Cellular Rejection on Cardiovascular Mortality in Cardiac Transplant Recipients: Defining Rejection Patterns. J Heart Lung Transplant 25:1277-82, 2006.
  3. Carlson R.W., et al. HER2 Testing in Breast Cancer: NCCN Task Force Report and Recommendations. J Natl Compr Canc Netw 4:Suppl 3:S1-22, 2006.
  4. Hammond M.E., et al. Addressing the Maintenance of Certification Challenge: The College of American Pathologists Response. Arch Pathol Lab Med 129:666-75, 2005.

Daniel F. Hayes, M.D.

  1. Wolff A.C., et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 25:118-45, 2007.
  2. Wolff A.C., Hammond M.E.H., Schwartz J.N., Hayes D.F. Human Epidermal Growth Factor Receptor 2 Testing Recommendation—In Reply. J Clin Oncol 25:4021-3, 2007.

Scott Jewell, Ph.D.

  1. Yang E.V., et al. Norepinephrine Up-Regulates The Expression of Vascular Endothelial Growth Factor, Matrix Metalloproteinase (MMP)-2, and MMP-9 in Nasopharyngeal Carcinoma Tumor Cells. Cancer Res 66:10357-64, 2006.
  2. Srinivasan M., Sedmak D., Jewell S. Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids. Am J Pathol 161:1961-71, 2002.
  3. Jewell S.D., et al. Analysis of the Molecular Quality of Human Tissues: An Experience From the Cooperative Human Tissue Network. Am J Clin Pathol 118:733-41, 2002.

Paula Kim

  1. Kim P. Cost of Cancer Care: The Patient Perspective. J Clin Oncol 25:228-32, 2007.

Lance Liotta, M.D., Ph.D.

  1. Wulfkuhle J.D., Edmiston K.H., Liotta L.A., Petricoin E.F. Technology Insight: Pharmacoproteomics for Cancer—Promises of Patient-Tailored Medicine Using Protein Microarrays. Nat Clin Pract Oncol 3:256-68, 2006).
  2. Espina V., et al. Laser Capture Microdissection. Nat Protoc 1:586-603, 2006.
  3. Petricoin E.F., Belluco C., Araujo R.P., Liotta L.A. The Blood Peptidome: A Higher Dimension of Information Content for Cancer Biomarker Discovery. Nat Rev Cancer 6:961-7, 2006.
  4. Luchini A., et al. Smart Hydrogel Particles: Biomarker Harvesting: One-Step Affinity Purification, Size Exclusion, and Protection Against Degradation. Nano Lett 8:350-61, 2008.

Christopher J. Logothetis, M.D., Ph.D.

  1. McDonnell T.J., et al. Biomarker Expression Patterns That Correlate With High Grade Features in Treatment Naive, Organ-Confined Prostate Cancer. BMC Med Genomics, 2008.
  2. Mathew P., et al. Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer With Bone Metastases. Clin Cancer Res 13:5816-24, 2007.
  3. Chen N., et al. A Secreted Isoform of Erbb3 Promotes Osteonectin Expression in Bone and Enhances the Invasiveness of Prostate Cancer Cells. Cancer Res 67:6544-8, 2007.
  4. Efstathiou E., et al. Initial Modulation of the Tumor Microenvironment Accounts for Thalidomide Activity in Prostate Cancer. Clin Cancer Res 13:1224-31, 2007.

Scott D. Patterson, Ph.D.

  1. Severino M.E., DuBose R.F., Patterson S.D. Pharmacodynamic Biomarkers in Early Clinical Drug Development (Invited Feature). IDrugs 9:849-53, 2006.
  2. Davis M.T., Auger P., Spahr C., Patterson S.D. Cancer Biomarker Discovery via Low Molecular Weight Serum Proteome Profiling—Where Is the Tumor? Proteomics: Clin Appl 1:1545-58, 2007.
  3. McCaffery I., Fitzpatrick V.D., Wang S-W., Rossi J., Suggs S.V., Bao H., Ferbas J., Patterson S.D. Translation of Protein Biomarkers for Clinical Development. In: Clinical Proteomics: From Diagnosis to Therapy, J.E. Van Eyk and M.J. Dunn (eds), WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, pp. 633-51, 2008.

David F. Ransohoff, M.D.

  1. Ransohoff D.F. How to Improve Reliability and Efficiency of Research About Molecular Markers: Roles of Phases, Guidelines, and Study Design. J Clin Epidemiol 60:1205-19, 2007.
  2. Ransohoff D.F. Lessons From Controversy: Ovarian Cancer Screening and Serum Proteomics. J Natl Cancer Inst 97:315-9, 2005.
  3. Ransohoff D.F. Bias as a Threat to the Validity of Cancer Molecular-Marker Research. Nat Rev Cancer 5:142-9, 2005.
  4. Ransohoff D.F. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4:309-14, 2004.
  5. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., Turnbull B.A., Ross M.E. Fecal DNA versus Fecal Occult Blood for Colorectal-Cancer Screening in an Average-Risk Population. N Engl J Med 351:2704-14, 2004.

Dennis J. Slamon, M.D., Ph.D.

  1. Jones L.W., et al. Cardiovascular Risk Profile of Patients With HER2/neu-Positive Breast Cancer Treated With Anthracycline-Taxane-Containing Adjuvant Chemotherapy and/or Trastuzumab. Cancer Epidemiol Biomarkers Prev 16:1026-31, 2007.
  2. Hinestrosa M.C., et al. Shaping the Future of Biomarker Research in Breast Cancer to Ensure Clinical Relevance. Nat Rev Cancer 7:309-15, 2007.
  3. Finn R.S., et al. Dasatinib, an Orally Active Small Molecule Inhibitor of Both the Src and Abl Kinases, Selectively Inhibits Growth of Basal-Type/"Triple-Negative" Breast Cancer Cell Lines Growing In Vitro. Breast Cancer Res Treat 105:319-26, 2007.
  4. Slamon D.J., et al. Advances in Adjuvant Therapy for Breast Cancer. Clin Adv Hematol Oncol 4:Suppl 1:4-9, 2006.
  5. Press M.F., et al. Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials. Clin Cancer Res 11:6598-607, 2005.

Gerry Thomas, Ph.D.

  1. Detours V., et al. Genome Wide Gene Expression Profiling Suggests Distinct Radiation Susceptibilities in Sporadic and Post Chernobyl Papillary Thyroid Cancers. Br J Cancer 97:818-25, 2007.
  2. Grassl J., et al. Profiling the Breast Cancer Proteome-The New Tool of the Future? Clin Oncol 18:581-6, 2006.
  3. Unger K., et al. RET Rearrangements in Post-Chernobyl Papillary Thyroid Carcinomas With a Short Latency Analysed by Interphase FISH. Br J Cancer 94:1472-7, 2006.
  4. Powell N.G., et al. Frequency of BRAF T1794A Mutation in Thyroid Papillary Carcinoma Relates to Age of Patient at Diagnosis and Not to Radiation Exposure. J Pathol 205:558-64, 2005.
  5. Williams E.D., et al. Thyroid Carcinoma after Chernobyl. Latent Period, Morphology and Aggressivity. Br J Cancer 90:2219-24, 2004.
  6. Unger K., et al. Heterogeneity in the Distribution of RET/PTC Rearrangements Within Individual Post-Chernobyl Papillary Thyroid Carcinomas J Clin Endocrinol Metab 89:4272-9, 2004.

Paul Waring, M.D., Ph.D.

  1. Loughrey M.B., et al. Incorporation of Somatic BRAF Mutation Testing into an Algorithm for the Investigation of Hereditary Non-Polyposis Colorectal Cancer. Fam Cancer 6:301-10, 2007.
  2. Chenevix-Trench G., et al. Genetic and Histopathologic Evaluation of BRCA1 and BRCA2 DNA Sequence Variants of Unknown Clinical Significance. Cancer Res 66:2019-27, 2006.
  3. Tothill R.W., et al. An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin. Cancer Res 65:4031-40, 2005.

James L. Wittliff, Ph.D., M.D. hc

  1. Wittliff J.L., et al. Molecular Signatures of Estrogen Receptor-Associated Genes in Breast Cancer Predict Clinical Outcome. In: Proceedings: Fifth Annual Symposium on Hormonal Carcinogenesis.
    J.J. Li, S.A. Li, S. Mohla, H. Rochefort, T. Maudelone (eds), pp. 349-58, Springer Publications, NY, 2008.
  2. Wittliff J.L., Erlander, M.G. Laser Capture Microdissection and its Applications in Genomics and Proteomics. In: Laser Capture Microscopy and Microdissection. P. Michael Conn (ed.), Vol. 356, pp. 12-25, Academic Press/Elsevier Science, San Diego, CA, 2002.
  3. Fleisher M., Dnistrian A.M., Sturgeon C.M., Wittliff J.L. Practice Guidelines and Recommendations for Use of Tumor Markers in the Clinic. In: Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. D.P. Diamandis et al. (eds.), pp. 33-63, AACC Press, Washington, DC, 2002.
  4. Fisher B., et al. Prognosis and Treatment of Patients with Breast Tumors of One Centimeter or Less and Negative Axillary Lymph Nodes. J Natl Cancer Inst 93:112-20, 2001.
  5. Wittliff J.L., et al. Steroid and Peptide Hormone Receptors: Methods, Quality Control and Clinical Use. In: The Breast: Comprehensive Management of Benign and Malignant Diseases. K.I. Bland, E.M. Copeland III (eds.), Chapter 25, pp. 458-98, Philadelphia, PA, W.B. Saunders Co., 1998.